Literature DB >> 22465474

Downregulation of IRS2 in myelodysplastic syndrome: a possible role in impaired hematopoietic cell differentiation.

João Agostinho Machado-Neto1, Patricia Favaro, Mariana Lazarini, Adriana da Silva Santos Duarte, Leticia Fröhlich Archangelo, Irene Lorand-Metze, Fernando Ferreira Costa, Sara Teresinha Olalla Saad, Fabiola Traina.   

Abstract

Insulin receptor substrate 2 (IRS2) is an adaptor protein that associates with the receptor of erythropoietin, insulin-like growth factor 1 and thrombopoietin; however, its role is not known in myelodysplasia. We, herein, report a significantly lower IRS2 expression in MDS cells, compared to normal cells. IRS2 expression was reduced in high-risk, compared to low-risk disease, and positively correlated with neutrophil and platelet counts. IRS2 was upregulated during erythroid differentiation of CD34(+) cells from normal donors and low-risk MDS patients and also during erythroid, granulocytic and megakaryocytic differentiation in cell lines. These results suggest that defective IRS2 expression plays a role in the impaired hematopoietic cell differentiation in MDS.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22465474     DOI: 10.1016/j.leukres.2012.03.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.

Authors:  Bruna Alves Fenerich; Jaqueline Cristina Fernandes; Ana Paula Nunes Rodrigues Alves; Juan Luiz Coelho-Silva; Renata Scopim-Ribeiro; Priscila Santos Scheucher; Christopher A Eide; Cristina E Tognon; Brian J Druker; Eduardo Magalhães Rego; João Agostinho Machado-Neto; Fabiola Traina
Journal:  Signal Transduct Target Ther       Date:  2020-01-24

2.  IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.

Authors:  Paula de Melo Campos; João A Machado-Neto; Christopher A Eide; Samantha L Savage; Renata Scopim-Ribeiro; Adriana da Silva Souza Duarte; Patricia Favaro; Irene Lorand-Metze; Fernando F Costa; Cristina E Tognon; Brian J Druker; Sara T Olalla Saad; Fabiola Traina
Journal:  Oncotarget       Date:  2016-02-09

3.  CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells.

Authors:  Isabella Barbutti; Juliana M Xavier-Ferrucio; João Agostinho Machado-Neto; Lauremilia Ricon; Fabiola Traina; Stefan K Bohlander; Sara Teresinha Olalla Saad; Leticia Fröhlich Archangelo
Journal:  Oncotarget       Date:  2016-10-18

Review 4.  Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis.

Authors:  João Agostinho Machado-Neto; Bruna Alves Fenerich; Ana Paula Nunes Rodrigues Alves; Jaqueline Cristina Fernandes; Renata Scopim-Ribeiro; Juan Luiz Coelho-Silva; Fabiola Traina
Journal:  Clinics (Sao Paulo)       Date:  2018-10-11       Impact factor: 2.365

5.  DNLC: differential network local consistency analysis.

Authors:  Jianwei Lu; Yao Lu; Yusheng Ding; Qingyang Xiao; Linqing Liu; Qingpo Cai; Yunchuan Kong; Yun Bai; Tianwei Yu
Journal:  BMC Bioinformatics       Date:  2019-12-24       Impact factor: 3.169

Review 6.  Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.

Authors:  Panhong Gou; Wenchao Zhang; Stephane Giraudier
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

7.  NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.

Authors:  Bruna Alves Fenerich; Jaqueline Cristina Fernandes; Ana Paula Nunes Rodrigues Alves; Juan Luiz Coelho-Silva; Renata Scopim-Ribeiro; Priscila Santos Scheucher; Christopher A Eide; Cristina E Tognon; Brian J Druker; Eduardo Magalhães Rego; João Agostinho Machado-Neto; Fabiola Traina
Journal:  Signal Transduct Target Ther       Date:  2020-01-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.